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Abstract
The double-blinded placebo-controlled randomized study has been performed in 51 coronary heart disease (CHD)
patients to estimate the effects of time-released garlic powder tablets Allicor on the values of 10-year prognostic
risk of acute myocardial infarction (fatal and non-fatal) and sudden death, with the respect of secondary CHD pre-
vention. It has been demonstrated that 12-month treatment with Allicor results in the significant decrease of cardi-
ovascular risk by 1.5-fold in men (p < 0.05), and by 1.3-fold in women. The above results were equitable also in
terms of relative risks. The main effect that played a role in cardiovascular risk reduction was the decrease in LDL
cholesterol by 32.9 mg/dl in men (p < 0.05), and by 27.3 mg/dl in women. Thus, the most significant effects were
observed in men, while in women the decrease of cardiovascular risk appeared as a trend that might be due pre-
sumably to the insufficient sample size. Since Allicor is the remedy of natural origin, it is safe with the respect to
adverse effects and allows even perpetual administration that may be crucial for the secondary prevention of
atherosclerotic diseases in CHD patients.
Background
Coronary heart disease is the most common cause of
mortality. Risk factors for cardiovascular disorders
include: hyperlipidemia, hypertension, obesity, and glu-
cose intolerance. The social, medical and economical
burden of CHD and the other complications of advanced
atherosclerosis continue to increase in spite of the evi-
dent drop in cardiovascular death rates in the United
States of America and several European countries. This
fact is mostly due to the population ageing, the rapid
increase in the prevalence of type 2 diabetes mellitus and
obesity. These unfavorable tendencies are characteristic
for many industrial and developing countries, therefore
CHD remains the major cause of mortality and morbidity
in the world.
Many factors appear to contribute to the development
of atherosclerosis including alterations in plasma lipids
and lipoprotein levels, blood pressure regulation, platelet
function and clotting factors, etc. In recent years special
algorithms for the estimation of overall cardiovascular
risk based on the results of major epidemiological studies
have been developed, which allow for the complex
impact of different risk factors [1]. On the other hand,
current approaches to the prevention of atherosclerotic
diseases usually employ the effect on isolated risk factors.
However, the polyetiological nature of atherosclerosis
allows for the suggestion that simultaneous complex
reduction of several risk factors appears to be the most
valid and clinically effective way for primary prevention
of cardiovascular diseases. Several studies revealed that a
reduction in blood pressure reduces the risk and inci-
dence of cardiovascular diseases [2,3].
Garlic (Allium sativum L. fam. Alliaceae) is one of the
best-researched herbal remedies. Traditionally, it has
been employed to treat infections, rheumatism, heart
disease, diabetes, and many other disorders. Experimen-
tally, it has been shown to exert antihypertensive, anti-
bacterial, and hypoglycemic actions [4]. Clinically, garlic
has been evaluated for a number of conditions, includ-
ing hypertension, hypercholesterolemia, diabetes, and for
* Correspondence: sobenin@cardio.ru
1Institute of General Pathology and Pathophysiology, Russian Academy of
Medical Sciences, Moscow 125315, Russia
Full list of author information is available at the end of the article
Sobenin et al. Lipids in Health and Disease 2010, 9:119
http://www.lipidworld.com/content/9/1/119
© 2010 Sobenin et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
the prevention of arteriosclerosis and cancer [4]. Several
studies have indicated that garlic and its constituents
inhibit key enzymes involved in cholesterol and fatty
acid synthesis [5-8]. However, the clinical evidence is far
from compelling.
Garlic powder tablets, Allicor, were used as the drug
capable of reducing different risk factors [9]. Garlic con-
tains a number of biologically active compounds and
is widely used as traditional medicine in many cultures.
In recent years, antiatherosclerotic and cardiovascular-
protective effects of garlic have been extensively evalu-
ated. Evidence from numerous studies demonstrate that
garlic-based preparations can bring about the normaliza-
tion of plasma lipids, along with the enhancement of
fibrinolytic activity, inhibition of platelet aggregation
and reduction of blood pressure[10]. It has been also
shown that garlic inhibits human squalene monooxygen-
ase and HMG-CoA reductase, enzymes involved in cho-
lesterol biosynthesis [11].
The present study was performed to evaluate the
effectiveness of Allicor treatment in primary CHD pre-
vention and its effects on the estimates of multifunc-
tional cardiovascular risk. It was investigated the effects
of time-released garlic powder tablets Allicor on the
values of 10-year prognostic risk of acute myocardial
infarction and sudden death, with the respect of second-
ary CHD prevention.
Introduction
Clinical manifestations of atherosclerosis, mainly, CHD
and myocardial infarction, remain the leading cause of
mortality, morbidity, illness and disability in populations
worldwide. Atherosclerosis is an important medical and
social problem, so, the mechanisms of its development
and progression are an important field of investigations.
At present, a group of numerous clinical and biochem-
ical conditions (risk factors) tightly associated with the
development of atherosclerotic diseases is revealed on
the basis of the results of prospective epidemiological
studies. Usually, the strategy for prevention of cardiovas-
cular diseases is aimed to the reduction of risk factors,
and modern recommendations demand vigorous control
of multiple risk factors, including regulation of lipid
metabolism, blood pressure, coagulation and fibrinolysis
systems and others. The polyetiological nature of ather-
osclerosis allows the suggesting that simultaneous com-
plex reduction of several risk factors appears to be the
most valid and clinically effective way to the prevention
of cardiovascular diseases. In recent years the algorithm
for the assessment of multifunctional cardiovascular risk
was developed from the data of PROCAM Study, that is
suitable for use in CHD patients for the prediction of
such cardiovascular events as myocardial infarction and
sudden death. This model of risk assessment allows the
estimation of the effects of different drugs that can
modify risk factors on the dynamics of changes in cardi-
ovascular risk that incredibly increases with ageing.
Garlic-based preparations are thought to be promising
agents for multifunctional risk reduction, since biologi-
cally active components of garlic possess a wide range
of cardioprotective effects, such as lowering total and
LDL cholesterol, increasing HDL cholesterol, lowering
arterial blood pressure in mildly hypertensive subjects,
enhancing fibrinolysis, and inhibiting platelet aggrega-
tion etc. [11,12]. However, the effectiveness of garlic-
based drugs in secondary prevention of cardiovascular
diseases is still obscure. The present double-blinded pla-
cebo-controlled randomized study has been performed
to estimate the effects of time-released garlic powder
tablets Allicor on the values of 10-year prognostic risk
of acute myocardial infarction (fatal and non-fatal) and
sudden death, with the respect of secondary CHD pre-
vention in CHD patients.
Patients and Methods
The study was performed in the department of primary
prevention of cardiovascular diseases at Moscow Munici-
pal Cardiology Health Center. Patients with documented
CHD, men and women aged 40-65 years, who had a
serum cholesterol level above 200 mg/dl (5.2 mmol/L)
upon primary examination, were eligible for inclusion.
The absence of high arterial hypertension (systolic blood
pressure above 160 mm Hg or diastolic blood pressure
above 95 mm Hg), or lipid-lowering drugs administration
were also regarded as inclusion criteria. For randomiza-
tion, patients were stratified according to gender, age, total
cholesterol and smoking history. Two groups were
formed, one who received Allicor (coated tablets contain-
ing 150 mg garlic powder, INAT-Farma, Moscow, Russia)
one tablet twice a day for 12 months, and the other who
received a placebo in the same manner. Allicor and
placebo tablets looked identically.
Clinical and biochemical examination was performed
upon the inclusion at the end of the study. Venous
blood taken after overnight fasting was used for total
cholesterol, triglycerides and high density lipoprotein
(HDL) cholesterol measurements with commercial enzy-
matic kits (Boehringer Mannheim GmbH, Germany).
Low density lipoprotein (LDL) cholesterol was calcu-
lated according to Friedewald formula.
Ten-year prognostic risk of fatal or non-fatal myocar-
dial infarction and sudden death was calculated with
Cox proportional hazards model derived from PROCAM
study [13], where the following variables were used: gen-
der, age, systolic blood pressure, total cholesterol, trigly-
cerides, smoking status, diabetes mellitus, family history
of acute myocardial infarction in 1st degree relatives that
occurred before the age of 60 years and after risk
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calculation, the regional adjustment factor was applied
[14,15].
The significance of differences was estimated using
SPSS 10.1.7 program package (SPSS Inc., USA). After
the examination of variable distribution, the Mann-
Whitney statistics or t-test was used for between-group
comparisons, Wilcoxon statistics was used for within-
group effect assessments, and Pearson’s chi-square sta-
tistics was used for the comparison of nominal variables
distributions. To estimate the relationship between
changes in risk values and clinical and biochemical vari-
ables, Pearson’s correlation analysis and regression ana-
lysis were used. The data is presented in terms of mean
and S.E.M.; significance was defined at the 0.05 level of
confidence.
Results
Before the study, 92 patients were screened, and accord-
ing to inclusion criteria 63 patients were recognized as
eligible and randomized into two groups. Allicor-treated
group consisted of 33 patients (18 men, 15 women), and
placebo group consisted of 30 patients (17 men, 13
women). During the study, 7 patients (4 men, 3 women)
dropped out of Allicor group, and 5 patients (3 men,
2 women) were lost in placebo group. The reason for
the exclusion from the study was the discontinuation of
study medication. So, the retirement accounted for
21.2% and 16.7% in Allicor-treated and placebo groups,
respectively, and the difference between groups was not
statistically significant. By the end of the study there
were 26 evaluable patients in the Allicor-treated group
(14 men, 12 women) and 25 in the placebo group
(14 men, 11 women).
The baseline clinical data on evaluable patients are
presented in Table 1. It can be seen that groups of
patients did not differ significantly in all clinical vari-
ables, except the rate of smoking that was higher in
Allicor recipients. In the placebo group, mean age was
higher in women than in men (p < 0.05); with the
respect to other variables, men and women did not dif-
fer significantly within groups.
Baseline lipid values are presented in Table 2. Allicor
and placebo groups did not differ significantly in mean
total cholesterol, HDL and LDL cholesterol and trigly-
cerides levels. In placebo group, men and women dif-
fered significantly with the respect to HDL cholesterol
(p < 0.05). In the Allicor-treated group, serum triglycer-
ide levels were higher and HDL cholesterol was lower in
men as compared to women, but the differences did not
reach a statistical significance.
The changes in lipid levels that occurred during the
study are shown in Table 2, as well. In the placebo
group, no statistically significant changes were observed,
except to triglycerides that lowered by 16.4% (95% CI:
5.1; 36.6 mg/dl, p = 0.004) from the baseline. However,
in placebo-treated men the changes were rather promi-
nent: total cholesterol decreased by 7.9% (95% CI: 3.7;
37.1 mg/dl, p = 0.020), LDL cholesterol decreased by
10.0% (95% CI: 1.3; 36.2 mg/dl, p = 0.048) and triglycer-
ides decreased by 18.6% (95% CI: -1.1; 50.7 mg/dl, p =
0.030) from the baseline. On the opposite, in placebo-
treated women only a slight insignificant decrease in
serum triglycerides by 13.1% from the baseline was
observed.
In Allicor-treated patients there were significant
changes in total and LDL cholesterol levels. Total choles-
terol decreased by 12.4% (95% CI: 12.3; 54.8 mg/dl, p =
0.004), and LDL cholesterol decreased by 16.3% (95% CI:
14.8; 45.8 mg/dl, p = 0.001) from the baseline. Choles-
terol-lowering effects differed significantly from the pla-
cebo group (p = 0.038). Serum triglycerides lowered
insignificantly by 11.8% from the baseline. Like in
placebo group, the changes in lipid levels were more pro-
minent in men than in women. So, the total cholesterol
Table 1 Clinical Characteristics of Patients at the Baseline
Allicor Placebo
Variable All Men Women All Men Women
(n = 26) (n = 14) (n = 12) (n = 25) (n = 14) (n = 11)
Age, years 56.7 ± 1.8 53.6 ± 1.9 60.3 ± 2.9 56.3 ± 1.7 52.6 ± 1.9 60.9 ± 2.4$
SBP, mm Hg 134.2 ± 2.8 130.4 ± 3.8 138.8 ± 3.9 130.8 ± 3.1 129.3 ± 4.4 132.7 ± 4.3
DBP, mm Hg 82.5 ± 1.9 82.1 ± 2.6 82.9 ± 2.9 81.0 ± 1.7 81.4 ± 2.5 80.5 ± 2.4
BMI, kg/m2 27.0 ± 0.9 27.2 ± 1.2 26.8 ± 1.5 27.9 ± 0.9 27.3 ± 1.0 28.6 ± 1.6
DM, n 0 0 0 0 0 0
LVH, n 3 2 1 3 2 1
MI, n 17 12 5 13 10 3
Smoking, n 8* 7 1 4 4 0
SBP, systolic blood pressure; DBP, diastolic blood pressure; BMI, body mass index, DM, type 2 diabetes mellitus; LVH, left ventricular hypertrophy; MI, myocardial
infarction in anamnesis.
* - significant difference from placebo, p < 0.05;
$ - significant difference between men and women within the group, p < 0.05.
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lowered by 14.4% (95% CI: 10.1; 69.7 mg/dl, p = 0.008),
LDL cholesterol lowered by 16.9% (95% CI: 12.8; 53.0
mg/dl, p = 0.009) from the baseline, and statistically
insignificant decrease in serum triglycerides by 18.4% was
observed. In Allicor-treated women total cholesterol
decreased by 10.0% (95% CI: -8.8; 61.0 mg/dl, p = 0.182)
and LDL cholesterol lowered by 15.6% (95% CI: -0.4; 55.0
mg/dl, p = 0.060) from the baseline, but the changes did
not reach a statistical significance possibly due to insuffi-
cient sample size.
The data on the changes in the 10-year prognostic risk
of fatal and non-fatal myocardial infarction and sudden
death is presented in Table 3. Since the was a substan-
tial 8.5-fold difference in risk level between men and
women, the analysis of changes between Allicor-treated
and placebo groups without subdivision according to
gender is inappropriate. In placebo-treated women, the
risk of myocardial infarction and sudden death did not
change significantly, and in placebo-treated men the risk
lowered by 1.1-fold as compared to baseline (95% CI:
-1,5%; 5,1%, p = 0.041). In Allicor-treated women the
risk decreased by 1.3-fold (95% CI: -0.4%; 1.4%), but the
difference did not reach statistical significance (p =
0.239). In Allicor-treated men the significant 1.5-fold
decrease in risk level occurred (95% CI: -0.1%; 14.5%,
p = 0.019).
The data on the changes in relative risk of myocardial
infarction and sudden death is presented in Table 3, as
well. Since relative values were used, it became possible
to compare the between-group effects directly. In the
placebo group relative risk tended to rise mainly due to
the increase in age (95% CI: 0.79; 1.32), and in Allicor
recipients relative risk decreased by 1.25-fold (95% CI:
0.64; 0.99, p = 0.019). Additionally, in Allicor-treated
men the relative risk decreased by 1.3-fold (95% CI:
0.57; 0.94, p = 0.022). The main effect underlying the
decrease in risk of myocardial infarction and sudden
death in men was LDL cholesterol lowering (r = 0.409,
p = 0.031 for absolute risk changes, and r = 0.463,
p = 0.013 for relative risk changes).
Table 2 The Changes in Serum Lipid Levels
Allicor Placebo
Time All Men Women All Men Women
(n = 26) (n = 14) (n = 12) (n = 25) (n = 14) (n = 11)
Total cholesterol, mg/dl
At the baseline 269.2 ± 11.5 276.9 ± 16.3 260.2 ± 16.5 252.5 ± 9.1 259.4 ± 14.2 243.8 ± 10.4
After 12 months 235.7 ± 8.4* 237.0 ± 10.7* 234.1 ± 13.6 242.0 ± 6.9 238.9 ± 10.8* 245.8 ± 7.9
HDL cholesterol, mg/dl
At the baseline 50.9 ± 3.6 45.3 ± 3.4 57.3 ± 6.4 48.7 ± 2.5 43.8 ± 1.8 54.9 ± 4.6$
After 12 months 51.5 ± 3.1 45.0 ± 2.4 59.0 ± 5.5$ 50.7 ± 2.2 47.1 ± 2.2 55.2 ± 3.8
Triglycerides, mg/dl
At the baseline 162.1 ± 19.5 182.1 ± 30.7 138.8 ± 22.0 127.8 ± 9.7 133.4 ± 12.9 120.6 ± 15.0
After 12 months 142.9 ± 16.5 148.6 ± 26.5 136.3 ± 19.2 106.9 ± 6.8* 108.6 ± 8.2* 104.8 ± 11.7
LDL cholesterol, mg/dl
At the baseline 185.9 ± 9.3 195.2 ± 11.6 175.1 ± 14.8 178.3 ± 9.1 188.9 ± 13.5 164.8 ± 10.9
After 12 months 155.6 ± 7.8*# 162.3 ± 9.0* 147.8 ± 13.3 169.9 ± 7.2 170.1 ± 11.3* 169.6 ± 8.5
* - a significant difference from the baseline, paired Wilcoxon test, P < 0.05;
# - a significant difference from placebo, Mann-Whitney test, P < 0.05;
$ - a significant within-group difference between men and women, t-test, P < 0.05.
Table 3 The Changes in 10-years Prognostic Risk of Myocardial Infarction and Sudden Death
Allicor Placebo
Time All Men Women All Men Women
(n = 26) (n = 14) (n = 12) (n = 25) (n = 14) (n = 11)
Absolute risk, %
At the baseline 13.1 ± 3.8 22.3 ± 6.0 2.3 ± 0.6$ 8.9 ± 2.4 14.3 ± 3.7 2.0 ± 0.7$
After 12 months 8.9 ± 2.3* 15.1 ± 3.5* 1.8 ± 0.6$ 7.8 ± 2.4* 12.4 ± 3.9* 1.9 ± 0.6$
Relative risk
At the baseline 1.00 1.00 1.00 1.00 1.00 1.00
After 12 months 0.81 ± 0.08* 0.76 ± 0.08* 0.88 ± 0.15 1.05 ± 0.13 0.81 ± 0.10 1.36 ± 0.23$
* - a significant difference from the baseline, paired Wilcoxon test, P < 0.05;
$ - a significant within-group difference between men and women, t-test, P < 0.05.
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Discussion
The results of the given study have demonstrated that a
12-month treatment of CHD patients with garlic powder
tablets Allicor results in the decrease of multifunctional
prognostic risk of myocardial infarction and sudden
death either prevents the rise of risk with ageing. The
above effects were similar with the respect of absolute as
well as relative risks. The most significant effects were
observed in men, while in women the decrease of cardio-
vascular risk appeared as a tendency that might be due
presumably to the insufficient sample size. It is notable
that men differed from women significantly with the
respect to a baseline prognostic risk level. This difference
is based on the peculiarities of risk estimation algorithm,
while in the PROCAM study only 32 myocardial infarc-
tions occurred during the 10 year follow-up in 2,810
women aged 45-65, as compared to 325 events in 4,818
men in the same age group [13].
The results of major epidemiological studies have pro-
vided the evidence of cardiovascular risk determination
by multifunctional effects of different risk factors, such as
gender, age, family anamnesis, diabetes mellitus, dyslipi-
daemia, arterial hypertension, smoking history, and
abdominal obesity, etc. [16]. The main approach in sec-
ondary CHD prevention is meaningfully based on the
treatment of major risk factors. During the last decade,
the conception of absolute multifunctional prognostic
risk estimation that provides actual probability of acute
cardiovascular event became prevailing in the planning of
preventive therapy. The algorithms of multifunctional
risk assessment gives better results even than the elevated
LDL cholesterol level, the parameter that exceeds other
isolated risk factors in terms of sensitivity and specificity
[17]. The reason is that several risk factors can clusterize,
thus increasing the probability of acute cardiovascular
event in synergistic manner [18,19].
According to the polyetiological nature of atherosclero-
tic diseases, the key interventions in secondary CHD pre-
vention include the correction of lipid metabolism, blood
pressure control and smoking cessation. The lowering of
blood cholesterol is traditionally regarded as the main
method of CHD prevention. Indeed, the main effect of
Allicor treatment that provided the decrease of multifunc-
tional prognostic risk of myocardial infarction and sudden
death in the given study was the significant decrease in
total and LDL cholesterol. Lipid-lowering properties of
garlic-based drugs and preparations are studied rather well
[11,20,21], and in spite of the presence of contradictory
results [18], the meta-analysis of performed clinical trials
indicates that garlic treatment produces moderate hypoli-
pidemic effect that may be quite comparable to rational
dietary treatment [12,19]. Additionally, garlic-based pre-
paration may produce moderate hypotensive effects in
patients with mild or moderate arterial hypertension, and
in some studies the increase of HDL cholesterol was
demonstrated [10,22-26]. It is notable that garlic prepara-
tions influence significantly on platelet aggregation and
plasma fibrinolytic activity that may alter the actual risk of
myocardial infarction [16,21,27,28]. Although the last
parameters are not taken in consideration in the algo-
rithms of multifunctional risk estimation, they clearly act
as independent and significant variables in the risk of car-
diovascular events.
Garlic contains different biologically active compo-
nents and sulfur-containing amino acids, such as allicin,
ajoene, S-allylcysteine, S-methylcysteine, diallyl disulfide
and sulfoxides, that may be responsible for antiathero-
sclerotic activity of garlic realized through different
mechanisms of action [29,30]. Allicor contains garlic
powder that is considered to retain the biologically
active ingredients of raw garlic, both water-soluble and
organic-soluble, in a better manner [31-33]. In contrast
to other garlic-based drugs that are present at the mar-
ket, Allicor possess a prolonged mode of action, since
its biological effects last for 12-16 hours after single
dose administration [34]. Since Allicor is the remedy of
natural origin, it is safe with the respect to adverse
effects and allows even the perpetual administration that
may be crucial for the secondary prevention of athero-
sclerotic diseases in CHD patients.
Conclusion
We have demonstrated that a 12-month treatment with
Allicor results in the significant decrease of cardiovascular
risk by 1.5-fold in men, and by 1.3-fold in women. The
main effect that played a role in cardiovascular risk reduc-
tion was the decrease in LDL cholesterol by 32.9 mg/dl in
men, and by 27.3 mg/dl in women. Thus, the most signifi-
cant effects were observed in men, while in women the
decrease of cardiovascular risk appeared as a trend that
might be due presumably to the insufficient sample size.
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